Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $19.24, but opened at $20.14. Ascentage Pharma Group International shares last traded at $20.2150, with a volume of 651 shares trading hands.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AAPG. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. BTIG Research reissued a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, June 15th. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. B. Riley Financial started coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat, Ascentage Pharma Group International has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Performance

The company’s fifty day simple moving average is $18.84 and its 200 day simple moving average is $22.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently made changes to their positions in AAPG. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International in the third quarter valued at approximately $383,000. UBS Group AG lifted its holdings in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the second quarter worth $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.